TY - JOUR T1 - Macrolide and fluoroquinolone resistance of <em>Mycoplasma genitalium</em> in southern Spain, 2018–2019 JF - Sexually Transmitted Infections JO - Sex Transm Infect SP - 8 LP - 10 DO - 10.1136/sextrans-2019-054386 VL - 97 IS - 1 AU - Adolfo de Salazar AU - Antonio Barrientos-Durán AU - Beatriz Espadafor AU - Ana Fuentes-López AU - Natalia Chueca AU - Federico Garcia Y1 - 2021/02/01 UR - http://sti.bmj.com/content/97/1/8.abstract N2 - Objectives In recent years, resistance in Mycoplasma genitalium (MG) to first-line (azithromycin) and second-line (moxifloxacin) treatment has been increasingly reported worldwide, however, no data regarding the south of Spain are available.Methods To determine resistance rates, MG-positive samples collected from June 2018 to June 2019 were analysed by sequencing the 23S rRNA and parC genes.Results A total of 77 patients (24 men having sex with men (MSM), 30 heterosexual men and 23 women) were included. Resistance-associated mutations against macrolide and fluoroquinolones were found in 36.4% (95% CI 25.7% to 48.1%) and 9.1% (95% CI 3.7% to 17.8%) of the patients, respectively. Being MSM and having had another STI in the last year were significantly associated with macrolide-resistant MG infection, while no associations were found with resistance to fluoroquinolones.Conclusions Testing for resistance to first-line and second-line drugs against MG should be recommended for the general population and mandatory for the MSM population. We suggest that empiric azithromycin use for STI management should be avoided. ER -